

DAFTAR PUSTAKA

1. Cho NH, Shaw JE, Karuranga S, Huang Y, Rocha FJD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Research and Clinical Practice*. 2018;138:271-81.
2. American Diabetes Association (ADA). Standard of medical care in diabetes-2017. *Diabetes Care*. 2017;40:1-44.
3. International Diabetes Federation (IDF). IDF diabetes atlas eight edition 2017. International Diabetes Federation. 2017;8:14-39.
4. Kemenkes RI. Riset kesehatan dasar (RISKESDAS) 2013. Jakarta: Balai Penelitian dan Pengembangan Kesehatan; 2013. Diakses dari: <http://www.depkes.go.id/resources/download/general/Hasil%20Riskasdas%202013.pdf> November 2018.
5. Perkumpulan Endokrinologi Indonesia (PERKENI). Konsensus pengendalian dan pencegahan diabetes melitus tipe 2 di Indonesia. Jakarta: PB PERKENI. 2015.
6. Shokri F, Ghaedi H, Fard SG, Movagh A, Abediankenari S, Mahrooz A, et al. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients. *International Journal of Molecular and Cellular Medicine*. 2016;5:1-7.
7. Wang YW, He SJ, Feng X, Cheng J, Lou YT, Tian L, et al. Metformin: a review of its potential indications. *Drug Design Development and Therapy*. 2017;11:2421-9.
8. Susilowati E. The minor allele frequency of metformin transporter gene: SLC22A1 rs628031 A>G among the Indonesian healthy subjects. *Prosiding APC Universitas Sebelas Maret*. 2018;2:121-9.
9. Xiao D, Guo Y, Li X, Yin JY, Zheng W, Qiu XW, et al. The impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms on metformin therapeutic efficacy in Chinese type 2 diabetes patients. *International Journal of Endocrinology*. 2016;2016:1-7.
10. Nardi CA, Koepsell H, Anglada MP. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses and drug-drug interactions. *The Pharmacogenomics Journal*. 2015;15(6):1-15.
11. Sur D. A tale of genetic variation in the human SLC22A1 gene encoding oct1 among type 2 diabetes melitus population groups of West Bengal, India. *IMPACT International Journal of Research in Applied, Natural and Social Sciences*. 2014;2(5):97-106.
12. Kang HJ, Song IS, Ho JS, Kim WY, Lee CH, Shim JC, et al. Identification and functional characterization of genetic variants of human organic cation transporter in a Korea population. *Drug Metabolism and Disposition*. 2007;35(4):667-75.

13. Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, et al. Seven single nucleotide polymorphisms in the SLC22A1 gene encoding human organic cation transporter (oct 2). *Drug Metabolism and Pharmacokinetics*. 2004;19(4):308-12.
14. Zhou Y, Ye W, Wang Y, Jiang Z, Meng X, Xiao Q, et al. Genetic variants of OCT1 influence glycemc response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. *International Journal of Clinical and Experimental Pathology*. 2015;8(8):9533-42.
15. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, et al. Human organic cation transporter (oct1 and oct2) gene polymorphisms and therapeutic effects of metformin. *Journal of Human Genetics*. 2007;52:117-22.
16. American Diabetes Association. *Diagnosis and classification of diabetes mellitus*. *Diabetes Care*. 2010;33:62-9.
17. Kurniawati E. *Diabetes mellitus*. *Jurnal Kedokteran Universitas Lampung*. 2014;4(7):114-9.
18. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. *International Journal of Medical Sciences*. 2014;11(11):1185-200.
19. Lipoeto NI, Yerizel E, Edward Z, Widuri I. Hubungan nilai antropometri dengan kadar glukosa darah. *Medika*. 2007;186:23-8.
20. Setiati S, editor. *Buku ajar ilmu penyakit dalam jilid III*. Edisi ke 6. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia. 2014.
21. Price SA. *Patophysiology: clinical concepts of disease process volume 2*. Edisi ke 6. Jakarta: EGC. 2006:1259-74.
22. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009;58(4):773-95.
23. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. *Diabetes Care*. 2013;36:127-38.
24. Hamasaki H. Daily physical activity and type 2 diabetes: a review. *World Journal of Diabetes*. 2016;7(12):243-51.
25. Goodman and Gilman's. *The pharmacological basis of therapeutics 12th edition*. New York: McGraw Hill Education. 2011:1258-9.
26. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenetics Genomics*. 2012;22(11):820-7.
27. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia*. 2017;60:1577-85.
28. Lorensia A, Gorisalam E. Analisis masalah terkait pengobatan antidiabetes pada pasien sirosis hati dengan diabetes mellitus tipe 2 di suatu rumah sakit di surabaya. *Jurnal Ilmiah Sains dan Teknologi*. 2016;2(9):58-73.

29. Compean DG, Quintana JOJ, Gonzales JAG, Garza HM. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implication and management. *World Journal of Gastroenterology*. 2009;15(3):280-8.
30. Graham GG, Punt J, Arora M, Day RO, Dooge MP, Doung JK, et al. Clinical Pharmacokinetics of metformin. *Clinical Pharmacokinetics*. 2011;50(2):81- 98.
31. Sitohang RC, Ramadhani R, Tahapary DL. Efikasi dan keamanan obat antidiabetik oral pada pasien diabetes melitus tipe 2 dengan penyakit ginjal kronik. *Jurnal Penyakit Dalam Indonesia*. 2018;3(5):150-5.
32. Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C. Genetic analysis of oct1 gene polymorphisms in Indian population. *Indian Journal of Human Genetics*. 2011;17(3):164-8.
33. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. *Pharmacogenomics*. 2008;9(4):415-22.
34. Cho SK, Kim CO, Park ES, Chung JY. Verapamil decrease the glucose-lowering effect of metformin in healthy volunteers. *British Journal of Clinical Pharmacology*. 2014;78(6):1426-32.
35. Frank R, Gardner E, Sparreboom A, Pharmacogenetics of drug transporter. *Current Pharmacogenomics and Personalized Medicine*. 2016;2(16):220-30.
36. Mato PM, Fokeng MG, Essop MF, Owira PMO. Genetic polymorphisms of organic cation transporter 1 (oct1) and responses to metformin therapy in individuals with type 2 diabetes mellitus. *Systematic Reviews*. 2018;7:1-6.
37. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Strayke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, oct1. *Proceeding of the National Academy of Sciences*. 2003;10(100):5902-7.
38. Ningrum VDA, Ikawati Z, Sadewa AH, Ikhsan MR. Allele frequencies of two main metformin transporter genes: SLC22A1 rs628031 A>G and SLC47A1 rs2289669 G>A among the Javanese population in Indonesia. *Current Pharmacogenomics and Personalized Medicine*. 2017;15:121-8.
39. Galardo N, Pellizzari EH, Meroni SB, Cigorraga SB, Shackelford DB, Shaw RJ, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. *Journal of Clinical Investigation*. 2009;117(5):563-75.
40. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, et al. Effect of genetic variation in the organic cation transporter 1 on metformin pharmacokinetics. *Clinical Pharmacology & Therapeutics*. 2010;83(2):273-80.
41. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. *Pharmacogenomics Journal*. 2009;9(4):247-7.

42. Malinda H, Rahmawati, Hendra H. Gambaran penggunaan obat antidiabetik pada pengobatan pasien diabetes melitus tipe 2 rawat jalan di RSUP Dr Wahidin Sudirohusodo Makassar. *As-Syifaa Jurnal*. 2015;07(01):93-102.
43. Romadhoni HA. Analisis efektivitas biaya penggunaan metformin atau glimepiride pada penderita diabetes melitus tipe 2 rawat jalan di rumah sakit pku Muhammadiyah Delanggu 2016 [Skripsi]. 2018;1-11.
44. Malin SK, Kashyap SR. Effects of metformin on weight loss. *Current Opinion in Endocrinology, Diabetes and Obesity*. 2014;21(5):323-9.
45. Wijaya IN, Faturrohman A, Yuda A, Mufarihah. Profil penggunaan obat pada pasien diabetes melitus di puskesmas wilayah Surabaya Timur. *Jurnal Farmasi Komunitas*. 2015;2(1):23-8.
46. Kurniawaty E, Yanita B. Faktor-faktor yang berhubungan dengan kejadian diabetes melitus tipe 2. *Majority*. 2016;5(2):27-31.
47. Barbieri M, Rizzo MR, Manzella D, Paolisso G. Age-related insulin resistance: is it an obligatory finding? the lesson from healthy centenarians. *Diabetes Metabolism Research and Review*. 2011;17(1):19-26.
48. Khairani R. Prevalensi diabetes melitus dan hubungannya dengan kualitas hidup lanjut usia di masyarakat. *Universa Medicina*. 2007;26(1):18-26.
49. Al-Eitan LN, Almomani BA, Nassar AM, Elsqa BZ, Saadeh NA. Metformin pharmacogenetics: effects of SLC22A1, SLC22A2, and SLC22A3, polymorphism on glycemic control and HbA1c levels. *Journal Of Personalized Medicine*. 2019;9(17):1-11.

